Full Press Release Details
HELOCYTE ANNOUNCES CORPORATE AND CLINICAL
New York, New York - April 21,
2016 - Helocyte, Inc. a majority-owned subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) focused on the acquisition,
development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease (and
in particular, cytomegalovirus or "CMV"), today announced several corporate and clinical milestones.
is a clinical-stage company developing novel immunotherapies for the prevention and treatment of cancer and infectious disease
(and in particular, cytomegalovirus or "CMV"). The Centers for Disease Control estimate that 50 to 80 percent of Americans
are infected with CMV by the age of 40. While the virus is asymptomatic in healthy individuals, it can cause severe and life-threatening
disease in those with weakened or uneducated immune systems. Patients undergoing allogeneic stem cell and solid organ transplantation
are at particularly high risk of experiencing complications associated with CMV. Helocyte's PepVax and Triplex vaccines
are engineered to induce a robust and durable virus-specific T cell response to control CMV in transplant recipients. Helocyte's
Pentamer vaccine is designed to induce a neutralizing antibody response to prevent the transmission of CMV from mother to fetus,
the most common congenital infection. There is no approved therapy for the prevention or treatment of congenital CMV. While current
antiviral therapies have reduced the rate of CMV disease-related mortality in transplant recipients, such treatments have been
linked to increased toxicity, delayed immune reconstitution and late onset of CMV. The Helocyte vaccines can educate the body's
innate immune system to fight CMV. For more information, please visit www.helocyte.com.
About Fortress Biotech
Fortress Biotech, Inc. ("Fortress"
or "the Company") is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical
and biotechnology products. Fortress plans to develop and commercialize products both within Fortress and through subsidiary
companies, also known as Fortress Companies. In addition to its internal development programs, the Company will leverage
its biopharmaceutical business expertise and drug development capabilities to help the Fortress Companies achieve their goals.
Additionally, the Company will provide funding and management services to each of the Fortress Companies and, from time to time,
the Company and the Fortress Companies will seek licensing, partnerships, joint ventures and/or public and private financings
to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com.
Forward-Looking Statements
This press release may contain "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks
related to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships;
risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing
(including the risk that clinical data will not be reproduced in larger studies); our dependence on third party suppliers; our
ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described
in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward
looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by law.
Frank Taffy, Co-Founder, President, CEO and Board Member
Helocyte, Inc., 2 Gansevoort Street, 9th Floor, New
Phone, 212-554-4520 Email, frank@helocyte.com